Atin Agarwal, George J. Chang, Chung-Yuan Hu, Melissa Taggart, Asif Rashid, In J. Park, Y. Nancy You, Prajnan Das, Sunil Krishnan, Christopher H. Crane, Miguel Rodriguez-Bigas, John Skibber, Lee Ellis, Cathy Eng, Scott Kopetz and Dipen M. Maru Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy Cancer 119
Article first published online: 1 OCT 2013 | DOI: 10.1002/cncr.28331
The quantified pathologic response assessed as the percentage of residual tumor cells is a predictor of recurrence-free survival in patients with rectal cancer and stratifies patients with high pathologic stage disease. Patients with a complete or near-complete response have a low risk of disease recurrence. These findings have potential implications for prognosis and treatment strategies that rely on pathologic response to chemoradiotherapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field